Clinical and experimental treatment of residual immune activation in people living with HIV
Clinical and Experimental Immunology · 21.01.2025 · 219 (1)
DOI: 10.1093/cei/uxaf023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 17.04.2025. Verfasst von Krystelle Nganou-Makamdop. Beteiligte Einrichtung: Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: HIV Infections, Lymphocyte Activation, Anti-Inflammatory Agents, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Potent inflammatory responses stemming from innate and T cell activation are initiated during acute human immunodeficiency virus infection. Suppression of the virus replication by antiretroviral therapy reduces but does not normalize immune activation. By now, it is clear that residual immune activation can persist even after years of antiretroviral therapy and associates with increased risks for co-morbidities, thereby raising interest for strategies that can resolve the residual immune activation in people with human immunodeficiency virus on antiretrovirals. This brief review reports the human studies with various drugs with anti-inflammatory properties and their effects on measures of systemic immune activation on people with human immunodeficiency virus. Along with the possible reasons for conflicting outcomes, considerations for ongoing and future approaches are outlined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
ORCID-Profile: Krystelle Nganou-Makamdop
Zitieren
APA
Nganou-Makamdop, K. (2025). Clinical and experimental treatment of residual immune activation in people living with HIV. Clinical and Experimental Immunology, 219(1). https://doi.org/10.1093/cei/uxaf023
Vancouver
Nganou-Makamdop K. Clinical and experimental treatment of residual immune activation in people living with HIV. Clinical and Experimental Immunology. 2025;219(1). doi:10.1093/cei/uxaf023
BibTeX
@article{NganouMakamdop2025,
author = {Nganou-Makamdop, Krystelle},
title = {Clinical and experimental treatment of residual immune activation in people living with HIV},
journal = {Clinical and Experimental Immunology},
year = {2025},
volume = {219},
number = {1},
doi = {10.1093/cei/uxaf023}
}
EUVIMED